On July 6, Gelong Exchange, Rongchang Biological H shares rose more than 12% at one point, and now hit a three-month high of 54.65 Hong Kong dollars. Rongchang Biological A shares rose about 7% to 56.09 yuan.
At present, the company has approved two products to be listed in China, and launched the overseas clinical layout of the core varieties, initially showing the potential of transformation from biotechnology companies to pharmaceutical companies.
Huatai expects the company's core varieties to continue to achieve milestones in 2022, including the overseas phase III clinical launch of potential SLE indications for Tetaximab and the overseas clinical launch of UC for vidiximab.